Trial Profile
A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2022
Price :
$35
*
At a glance
- Drugs Estetrol (Primary)
- Indications Vasomotor symptoms
- Focus Therapeutic Use
- Acronyms E4 RELIEF
- Sponsors Donesta Bioscience
- 22 Oct 2019 According to a Mithra Pharmaceuticals media release, results were presented at the 13th Annual Meeting of the European Society of Gynecology (ESG) held from 16-19 October 2019 in Vienna, Austria.
- 06 Oct 2018 Results presented at the North American Menopause Society 2018 Annual Meeting
- 03 Oct 2018 According to a Mithra Pharmaceuticals media release, the results from this trial will be presented at the 29th Annual Meeting of the North American Menopause Society (NAMS), being held on 3-6 Oct 2018 in San Diego, CA.